VHIO: Working together to advance personalized and targeted therapies against cancer
JOSEP TABERNERO
Director
Biosketch
VHIO´s Clinical Research Program, incorporating multidisciplinary cancer teams, is dedicated to developing both novel agents directed to specific signaling pathways in cancer and new/redefined tools to diagnose cancer earlier and better predict response to treatment. We pioneer important studies involving both preclinical and early-drug development research studies and lead several phase I, II and III clinical trials designed to identify more effective, cancer therapies tailored to individual patients.
- Breast Cancer and Melanoma Group
- Early Clinical Drug Development Group
- Experimental Hematology Group
- Gastrointestinal and Endocrine Tumors Group
- Genitourinary, Central Nervous System (CNS) tumors, Sarcoma and Cancer of Unknown Primary Site Group
- Gynecological Malignancies Group
- Hereditary Cancer Genetics Group
- Oncology Data Science (ODysSey) Group
- Prostate Cancer Translational Research Group
- Radiation Oncology Group
- Radiomics Group
- Sarcoma Translational Research Group
- Thoracic Tumors & Head and Neck Cancer Group
- Tumor Immunology & Immunotherapy Group